Viridian Therapeutics, Inc. Common Stock Earnings Dividend

Viridian Therapeutics, Inc. Common Stock’s revenue jumped 278.67% since last year same period to $0.28Mn in the Q2 2026. On a quarterly growth basis, Viridian Therapeutics, Inc. Common Stock has generated 101.42% jump in its revenue since last 3-months.

Viridian Therapeutics, Inc. Common Stock’s net profit fell -26.19% since last year same period to $-127.12Mn in the Q2 2026. On a quarterly growth basis, Viridian Therapeutics, Inc. Common Stock has generated -21.18% fall in its net profits since last 3-months.

Viridian Therapeutics, Inc. Common Stock’s net profit margin jumped 66.67% since last year same period to -44760.21% in the Q2 2026. On a quarterly growth basis, Viridian Therapeutics, Inc. Common Stock has generated 39.84% jump in its net profit margins since last 3-months.

Viridian Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.97 - a 10.19% jump from last quarter’s estimates.

Viridian Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.97.

Viridian Therapeutics, Inc. Common Stock’s earning per share (EPS) fell -5% since last year same period to -1.05 in the Q2 2026. This indicates that the Viridian Therapeutics, Inc. Common Stock has generated -5% annual rate of fall in its earning per share (EPS) in the last 4 quarters.